Pacira BioSciences, Inc. (PCRX) Income Statement

Revenue growth has hovered in the low-to-mid single digits over the past year, with Q2 2026 showing 6.2% growth, a slight uptick from Q1's 5.0%. This stability indicates that EXPAREL's market penetration is plateauing, and the company's diversification efforts via ZILRETTA and iovera have yet to materially accelerate the top line. The lack of acceleration, despite the NOPAIN Act tailwind, suggests that volume gains are being offset by pricing pressures or competitive dynamics.

The gross margin expansion of nearly 200 basis points year-over-year indicates that the company is managing its cost of goods effectively, likely benefiting from manufacturing efficiencies. However, the operating margin of 2.2% is a stark contrast, with SG&A consuming over 47% of revenue. This suggests that the company's pricing power at the gross level is not translating into profitability due to the high fixed-cost sales structure and ongoing investment in commercialization.

The company's operating income has been volatile, with Q2 2026 showing a 49% decline year-over-year, even as revenue grew. This suggests that the company is not achieving operating leverage; instead, SG&A expenses are rising faster than revenue, likely due to increased sales force expansion or marketing efforts. The lack of scalability in the cost structure is a concern, as it implies that even modest revenue growth may not translate into meaningful profit improvement.

The company's cost structure is dominated by SG&A, which has remained stubbornly high at around 47-50% of revenue over the past year. This is a significant drag on profitability, as gross margins of 77% leave only 30% of revenue to cover R&D and other costs. The lack of expense discipline is evident, as SG&A growth of 3.6% year-over-year outpaced revenue growth of 6.2% in Q2 2026, indicating that the company is not scaling its cost base efficiently.

Excluding Q3 2024, the company's operating income has been positive but thin, ranging from $2.0M to $28.2M. The impairment charge in Q3 2024, likely related to the Flexion acquisition, created a one-time hit that distorts the historical trend. This suggests that the company's core operations are marginally profitable, but the high fixed-cost structure and ongoing investments leave little room for error. The lasting impact is that investors should normalize for such charges when evaluating the company's earnings power.